Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now

Wockhardt (NS:) shares jumped by 14% today as it completed the phase-3 pneumonia study of macrolide antibiotic Nafithromycin. However, if we talk about the valuations, as per InvestingPro+ some other companies in the Pharma sector may have more upside potential now. According to the Compare feature of InvestingPro+, Zydus Lifesciences Ltd (NS:) and Biocon (NS:) are attractively placed with potential upside of 24% and 21% respectively. Wockhardt, according to InvestingPro+ may have crossed its intrinsic value to be in the overvalued region now.